{"disease":{"id":"mds-eb","name":"mds eb"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02562443","title":"Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":372,"lead_sponsor_name":"Traws Pharma, Inc.","has_results":false},{"nct_id":"NCT05175508","title":"Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04636918","title":"Ikervis for DED Due to GVHD Post Allo-HSCT","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Singapore Eye Research Institute","has_results":false},{"nct_id":"NCT04599426","title":"Allogenic NK Cell Transfusion Azacitidine MDS-EB","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"The Second Hospital of Shandong University","has_results":false},{"nct_id":"NCT03338348","title":"Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"University of Ulm","has_results":false},{"nct_id":"NCT05933070","title":"A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Inmune Bio, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}